SAHA significantly improved the anticancer efficacy of olaparib in triple-negative breast cancer (TNBC) cells that expressed functional phosphatase and tensin homolog (PTEN) [32]. The gene discussed is PTEN; the disease is triple-negative breast carcinoma.